Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study

BACKGROUND: Isocitrate dehydrogenase-1 (IDH1) is mutated in up to 25% of cholangiocarcinomas, especially intrahepatic cholangiocarcinoma. Ivosidenib is an oral, targeted inhibitor of mutant IDH1 (mIDH1) approved in the USA for the treatment of mIDH1 acute myeloid leukaemia in newly diagnosed patient...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet Gastroenterol Hepatol
Hlavní autoři: Lowery, Maeve A, Burris, Howard A, Janku, Filip, Shroff, Rachna T, Cleary, James M, Azad, Nilofer S, Goyal, Lipika, Maher, Elizabeth A, Gore, Lia, Hollebecque, Antoine, Beeram, Muralidhar, Trent, Jonathan C, Jiang, Liewen, Fan, Bin, Aguado-Fraile, Elia, Choe, Sung, Wu, Bin, Gliser, Camelia, Agresta, Samuel V, Pandya, Shuchi S, Zhu, Andrew X, Abou-Alfa, Ghassan K
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7934945/
https://ncbi.nlm.nih.gov/pubmed/31300360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2468-1253(19)30189-X
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky